Best Oncology Companies in Austin, United States
The 31 best Oncology companies in Austin, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Aspira Women's Health.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Austin
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 13 mo ago | 85 85 → 60 (-29%) | — | WordPressApple iCloud MailMySQL+25 | — | — |
| 2 | Asuragen Molecular diagnostics and genetics company advancing precision medicine in oncology | $80M | 85 mo ago | 114 114 → 101 (-11%) | — | WordPressApple iCloud MailMicrosoft 365+19 | 349 patents Detection and analysis of repeat expansions and miRNA biomarkers in nucleic acids. | — |
| 3 | Mirna Therapeutics Developing microRNA-based oncology therapies for solid and hematologic cancers | $78M | 138 mo ago | 27 | Jose Carlos Gutierrez Ramos CEO & President | — | — | — |
| 4 | Mirna Therapeutics Developing microRNA-based therapeutics for cancer treatment. | $78M | 138 mo ago | 72 | — | — | — | — |
| 5 | Triumvira Immunologics Developer of T-cell therapies for treating cancers | $55M | 55 mo ago | 85 | Jonathan Bramson Co-Founder & Chairman | — | 48 patents Bispecific T‑cell engager therapeutics targeting Claudin‑18.2, GUCY2C, and GPC3 antigens. | — |
| 6 | Endocare Provider of cancer diagnostic and therapeutic instruments | $53M | 233 mo ago | 120 | — | — | 193 patents Medical cryosurgical devices and cryogen delivery systems for tissue ablation | — |
| 7 | Forbius Biotech innovator dedicated to advancing healthcare solutions for better health | $32M | 85 mo ago | 37 | — | — | — | — |
| 8 | PLUS THERAPEUTICS Provider of therapeutics for multiple cancer treatments | $24M | 20 mo ago | 20 20 → 27 (+35%) | Marc Hedrick CEO | WordPressBugHerdApple iCloud Mail+39 | — | — |
| 9 | Terapio Medical devices providing TENS therapy for pain relief and muscle stimulation | $10M | 173 mo ago | 2 | Casey Cunningham Co-Founder | — | 29 patents Radioprotective therapeutics using RLIP76 protein to prevent radiation‑induced mucositis | — |
| 10 | ABCODIA Provider of blood test to determine risk of ovarian cancer | $10M | 137 mo ago | 4 | — | — | — | — |
| 11 | Curtana Pharma US-based, early-stage biopharma developing transcription factor targeting small molecule therapeutics for… | $8M | 113 mo ago | 5 | Gregory Stein Co-founder | — | — | — |
| 12 | Genprex Developer of therapeutics to treat cancer at molecular level | $3M | 75 mo ago | 28 28 → 23 (-18%) | — | WordPressMySQLPHP+21 | 12 patents Cancer gene therapy vectors targeting NPRL2, TUSC2/TUSC4, and ALK-driven tumors | — |
| 13 | Onko Solutions Fedora: Open-source Linux distribution and web server software provider | $2M | 129 mo ago | 4 | Hector Torres Chairman & CEO | — | — | — |
| 14 | Austin CyberKnife Developer of radiation therapy for the treatment of trigeminal neuralgia & cancer | $850K | 188 mo ago | — | — | WordPressMySQLPHP+15 | — | — |
| 15 | Pelican Therapeutics Developing antibody to stimulate memory CD8+ cytotoxic T cells for the treatment of cancer. | $410K | 82 mo ago | 3 | — | — | — | — |
| 16 | Siva Therapeutics Developer of gold nanoparticle-based hyperthermia technology for cancer therapy | $400K | 47 mo ago | 5 | Len Pagliaro CEO | — | — | — |
Top 12 Oncology companies in Austin
#1
Public · Austin, Texas · founded 1993 · 85 employees$96.7Mraised▾
Provider of diagnostic solution for ovarian malignancy in women. It offers products OVA1 and OVERA to detect the risk of ovarian cancer for patients. It also offers its flagship product for the detection of risk heredity breast and ovary cancer; ASPiRA GenetiXSM testing which offers comprehensive genetic testing options with a gynecologic focus.
- Sep 2025Post IPO$3M
- Mar 2025Post IPO$1.4M
- Jun 2024Post IPO$1.9M
- Jul 2020Post IPO$11M
#2
Public · Austin, Texas · founded 1996 · 20 employees$23.6Mraised▾
Provider of therapeutics for multiple cancer treatments. It offers its propriety liposomal nanotechnology platform to help in the reformulation of cancer medicines and target drug delivery. Its leading candidate is DocePLUS which targets Small Cell Lung and others cancer Breast Ovarian Multiple Myeloma Kaposi's Sarcoma.
- Feb 2025Post IPO$3.7M
- Feb 2025Grant (prize money)$2M
- May 2024Post IPO—
- Aug 2022Grant (prize money)$17.6M
#3
Series A · Austin, Texas · founded 2015 · 85 employees$55Mraised▾
Developer of T-cell therapies for treating cancers. The proprietary T cell Antigen Coupler (TAC) technology provides better therapies for cancer patients. The lead therapeutic candidate of the company TAC01-HER2 is a CD19-directed T cell product that is used for the treatment of B cell malignancies and multiple myeloma.
- Mar 2022Series A—
- Aug 2020Series A$55M
#4
Acquired · Austin, Texas · founded 2006 · 114 employees$80Mraised▾
Molecular diagnostics and genetics company advancing precision medicine in oncology. They are dedicated to improving patient outcomes through innovative molecular diagnostic solutions. They specialize in developing and commercializing cutting-edge testing kits and services for inherited genetic disorders and cancer. Their portfolio includes a range of AmplideX genetics assay kits for inherited disorders and QuantideX qPCR kits for precision oncology. They offer molecular quality controls and OEM services. They leverage enabling technologies, assay chemistries, and bioinformatics to drive product development. They provide genetic testing solutions, including carrier screening. They are committed to advancing cancer care with precision oncology solutions, supporting research with targeted detection of molecular mutations. They offer diagnostic tests to monitor chronic myeloid leukemia. They provide resources, publications, and disease information. They operate in EMEA, providing solutions to European customers in genetics and oncology.
- Sep 2019Grant (prize money)$182.4K
- Sep 2019Grant (prize money)$227.1K
- Sep 2019Grant (prize money)$229.5K
- Jun 2019Grant (prize money)—
#5
Public · Austin, Texas · founded 2007 · 27 employees$77.8Mraised▾
Developing microRNA-based oncology therapies for solid and hematologic cancers. This is a biotechnology company focused on advancing cancer treatment through microRNA replacement therapy. They leverage innovative miRNA technology for solid and hematologic cancers. Their work involves research, development, and potential therapeutic applications in oncology. They are involved in glycoproteomics, glycosylation analysis, vaccine design, and personalized medicine through glycan characterization. They are also involved in bioengineering, DNA-encoded antibodies, and bioconjugation. They are also involved in real-time PCR reactions in clinical research labs.
- May 2015Series D$41.8M
- May 2014Grant (prize money)$25.1M
- Oct 2012Series C$34.5M
- Aug 2011Series A$1.5M
#6
Deadpooled · Austin, Texas · founded 2007 · 72 employees$77.8Mraised▾
Mirna Therapeutics, a clinical-stage biopharmaceutical company, develops microRNA-based oncology therapeutics. Its lead product candidate is MRX34, a mimic of naturally occurring microRNA-34 encapsulated in a liposomal nanoparticle formulation that is in Phase 1 clinical trial.
- Apr 2015Series D$41.8M
- May 2014Grant (prize money)$25.1M
- Nov 2012Series C$34.5M
- Aug 2011Seed$1.5M
#7
Acquired · Austin, Texas · founded 1996 · 120 employees$53.1Mraised▾
Endocare provides cancer diagnostic and therapeutic instruments. The company offers an integrated biplane ultrasound that helps physicians with precise color Doppler visualization for detection of the tumor. The company also offers surgical instruments for cryopreserving the cancer cells and software for planning the surgery.
- May 2007Series B$7M
- Oct 2006Series B$16M
- Mar 2005Series B$15.6M
- Series B$14.5M
#8
Acquired · Austin, Texas · founded 2011 · 37 employees$32.2Mraised▾
Biotech innovator dedicated to advancing healthcare solutions for better health. This organization focuses on research and development within the biotechnology sector, striving to create impactful advancements in healthcare. The company is committed to innovation, aiming to develop solutions that improve patient outcomes and overall well-being. They leverage scientific expertise and cutting-edge technologies to address unmet medical needs. The business model is centered around creating and delivering novel therapies and diagnostic tools. The company fosters a culture of continuous improvement and collaboration, driving progress in the field of biotechnology. They are dedicated to making a positive impact on global health through their innovative research and development efforts.
- Oct 2019Series C—
- Aug 2018Grant (prize money)$18.8M
- Feb 2018Grant (prize money)$675K
- May 2017Series B—
#9
Seed · Austin, Texas · founded 2013 · 5 employees$8.2Mraised▾
Curtana is a US-based, early-stage biopharma developing transcription factor targeting small molecule therapeutics for glioblastoma multiforme. Olig2 is a transcription factor that is essential to normal early brain development but is not found in mature brain cells and non-brain tissue. Curtana’s lead candidate, CT-179, directly targets the OLIG2 transcription factor that is highly expressed in all diffuse gliomas and is found in ~100% of GBM cells that are positive for the tumorigenic CD133 stem cell marker. In Aug.2017, the company completed the Pre-IND Submission for CT-179 for the treatment of Malignant Gliomas.
- May 2017Grant (prize money)$55.8K
- Feb 2017Seed—
- Feb 2017Grant (prize money)$53.8K
- Jan 2017Grant (prize money)$52.3K
#10
Series A · Austin, Texas · founded 2005 · 2 employees$9.9Mraised▾
Medical devices providing TENS therapy for pain relief and muscle stimulation. They offer certified Smart TENS units designed to ease aches in the feet, legs, and body. Their devices deliver electrical impulses to reduce pain signals and stimulate endorphin production, providing temporary relief for chronic and acute pain. The product line includes wireless units for on-the-go relief, 3-in-1 units with EMS muscle stimulation and massage modes, and circulation units specifically designed for leg and foot pain. Designed in Switzerland, the focus is on personal healthcare, providing reliable, safe, and effective solutions to improve the quality of life through natural pain relief. They are committed to supplying solutions that help users feel better naturally.
- May 2012Grant (prize money)$3M
- Jan 2012Series A—
- Nov 2009Series A$5M
- Apr 2009Grant (prize money)$559.1K
#11
Public · Austin, Texas · founded 2009 · 28 employees$3.1Mraised▾
Genprex is a developer of therapeutics to treat cancer at the molecular level. It offers Oncoprex, the lead product candidate injected with erlotinib, is a novel, pan-kinase inhibitor that works to induce apoptosis in cancer cells and control cell signaling and inflammatory pathways to treat tumors and cancer metastases at the molecular level. The therapies are used for the treatment of non-small cell lung cancer.
- Jul 2020Grant (prize money)$2.6M
- May 2020Post IPO$2.5M
- Feb 2020Post IPO$17.5M
- Jan 2020Post IPO$8M
#12
Funding Raised · Austin, Texas · founded 2017 · 4 employees$9.9Mraised▾
Provider of blood test to determine risk of ovarian cancer. The test is for women with specific gene mutations. It helps women delaying preventative surgery to understand their risk. Clinicians assess patient suitability for testing and explain clinical evidence.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Austin is moving
A read on the academic research around Oncology in Austin — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 58 papers.
- The University of Texas at Austin40
- Austin Health12
- Austin College7
- Austin Hospital1
- Austin Independent School District1
- Tumor microenvironment1→8
- Immune system1→8
- Immunotherapy1→3
- Tumor microenvironment1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.